Literature DB >> 3257243

Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-alpha.

S Yokota1, T D Geppert, P E Lipsky.   

Abstract

The capacity of human recombinant tumor necrosis factor-alpha (rTNF alpha) to modulate human T cell proliferation was examined. To examine the effect of rTNF alpha on the responding T cell directly, T cell activation was studied in the absence of viable accessory cells (AC). Highly purified AC-depleted peripheral blood T4 or T8 cells were stimulated with immobilized monoclonal antibodies to the cluster of differentiation (CD)3 molecular complex, an AC-independent stimulus. rTNF alpha augmented anti-CD3-stimulated T4 and T8 cell proliferation. The capacity of rTNF alpha to enhance T cell proliferation varied inversely with the density of immobilized anti-CD3 and the number of responding cells in each culture. The capacity of rTNF alpha to enhance antigen-induced T4 cell proliferation was also examined. Antigen-bearing paraformaldehyde-fixed antigen-presenting cells induced modest T4 cell proliferation when cultured in flat-bottomed wells; this response was enhanced by rTNF alpha. The results demonstrate that rTNF alpha has direct effects on T cells, facilitating their capacity to proliferate in response to mitogens and antigens. These data indicate that rTNF alpha may play an immunoregulatory role, enhancing the proliferation of T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257243

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

Review 1.  Death receptors couple to both cell proliferation and apoptosis.

Authors:  Ralph C Budd
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 2.  Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  FEBS Lett       Date:  2011-04-15       Impact factor: 4.124

Review 3.  Tumor necrosis factor and immunopathology.

Authors:  P F Piguet; G E Grau; P Vassalli
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

4.  Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock.

Authors:  D Aderka; P Sorkine; S Abu-Abid; D Lev; A Setton; A P Cope; D Wallach; J Klausner
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

5.  CD8+ T cell expansion in HIV/HCV coinfection is associated with systemic inflammation.

Authors:  E V Saidakova; K V Shmagel; L B Korolevskaya; N G Shmagel; V A Chereshnev
Journal:  Dokl Biol Sci       Date:  2017-07-13

6.  Synthetic macrophages: antigen presentation by liposomes bearing class II major histocompatibility complex (MHC) and membrane interleukin-1 (IL-1).

Authors:  O Bakouche; L B Lachman
Journal:  J Clin Immunol       Date:  1989-09       Impact factor: 8.317

7.  Species-specific TNF induction of thymocyte proliferation.

Authors:  M J Ehrke; R L Ho; K Hori
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.

Authors:  Thomas Calzascia; Marc Pellegrini; Håkan Hall; Laurent Sabbagh; Nobuyuki Ono; Alisha R Elford; Tak W Mak; Pamela S Ohashi
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

9.  Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: first steps towards monitoring process activity.

Authors:  E I Gusev; T L Demina; A N Boiko; B V Pinegin
Journal:  J Neurol       Date:  1994-07       Impact factor: 4.849

10.  Effects of gamma interferon, tumor necrosis factor alpha, and interleukin-2 on infection and proliferation of Theileria parva-infected bovine lymphoblasts and production of interferon by parasitized cells.

Authors:  J C DeMartini; C L Baldwin
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.